Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

82.47 -0.70 (-0.85%)
Streaming Delayed Price Updated: 11:40 AM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy ↗
Via Stocktwits
News headline image
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. 
Via Benzinga
News headline image
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
IONS Premarket Gains 2.4% After C-Suite Insider Sells $440K In Stock ↗
Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5-1 plan. 
Via Benzinga
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
News headline image
An Overview of Ionis Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Ionis (IONS) Q2 Revenue Soars 101% ↗
Via The Motley Fool
News headline image
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
Ionis (IONS) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug ↗
Ionis reports surprise Q2 profit, raises 2025 forecast after strong Tryngolza launch and royalty gains push revenue past expectations. 
Via Benzinga
News headline image
Ionis reports second quarter 2025 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - A Strong Technical Setup Worth Watching ↗
IONIS Pharmaceuticals (NASDAQ:IONS) shows strong technicals with an 8/10 rating and a high-quality setup pattern, making it a breakout candidate for traders. 
Via Chartmill
News headline image
Ionis to hold second quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma ↗
Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing. 
Via Benzinga
News headline image
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
From Biogen Inc.
Via GlobeNewswire
News headline image
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version. 
Via Investor's Business Daily
News headline image
Analyst Expectations For Ionis Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 14 Analysts ↗
 
Via Benzinga
News headline image
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to host 2025 virtual Annual Meeting of Stockholders
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts ↗
 
Via Benzinga
News headline image
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge ↗
Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new and existing drug products. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.